Evidence map›Paper›PMID 27339663›Full record

ReviewJournal of the American Society of Nephrology : JASN2016

The Current State of Peritoneal Dialysis.

Rajnish Mehrotra, Olivier Devuyst, Simon J Davies, David W Johnson

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the American Society of Nephrology : JASN, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 272 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
272citing papers in PubMed, 10 pooled it
21.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

272 citing papers in PubMed, 10 syntheses or guidelines pooled it, 559 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Renal failure · 2022
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Dynamic changes in serum albumin and ferritin indicate higher risk of early-onset peritonitis in peritoneal dialysis patients.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026
    Article
  19. Article
  20. Article

212 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 5 countries.

Rajnish MehrotraKidney Research Institute and rmehrotr@uw.edu.
Olivier DevuystInstitute of Physiology, University of Zurich, Zurich, Switzerland.
Simon J DaviesDepartment of Nephrology, Keele University, Staffordshire, United Kingdom; and.
David W JohnsonDepartment of Nephrology, Division of Medicine, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia.
Keele University · GBThe University of Queensland · AUUCLouvain · BEUniversity of Washington · US

Funding

Biological Determinants of Peritoneal Dialysis OutcomesR01DK099165 · NIDDK · UNIVERSITY OF WASHINGTON · PI MEHROTRA, RAJNISH · 2014 to 2018
$3.2M
NIDDK NIH HHS R01 DK099165
6 · The paper itself

Abstract

Technical innovations in peritoneal dialysis (PD), now used widely for the long-term treatment of ESRD, have significantly reduced therapy-related complications, allowing patients to be maintained on PD for longer periods. Indeed, the survival rate for patients treated with PD is now equivalent to that with in-center hemodialysis. In parallel, changes in public policy have spurred an unprecedented expansion in the use of PD in many parts of the world. Meanwhile, our improved understanding of the molecular mechanisms involved in solute and water transport across the peritoneum and of the pathobiology of structural and functional changes in the peritoneum with long-term PD has provided new targets for improving efficiency and for intervention. As with hemodialysis, almost half of all deaths on PD occur because of cardiovascular events, and there is great interest in identifying modality-specific factors contributing to these events. Notably, tremendous progress has been made in developing interventions that substantially reduce the risk of PD-related peritonitis. Yet the gains have been unequal among individual centers, primarily because of unequal clinical application of knowledge gained from research. The work to date has further highlighted the areas in need of innovation as we continue to strive to improve the health and outcomes of patients treated with PD.

Indexed as

Peritoneal DialysisCardiovascular DiseasesHumansKidney Failure, ChronicPeritoneumPeritonitisRisk FactorsTreatment Outcomecardiovascular diseaseend-stage renal diseaseLife-threatening dialysis complicationsperitoneal dialysisperitoneal membrane

Identifiers

PMID27339663
PMCPMC5084899
OpenAlexW2469939151

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.